What empiric antibiotic regimen should be used for a 78‑year‑old male with an indwelling urinary catheter, urine cultures positive for Enterococcus faecalis and Citrobacter freundii, and no known drug allergies?

Empiric Antibiotic Regimen for Catheter-Associated UTI with Enterococcus faecalis and Citrobacter freundii

For this 78-year-old male with an indwelling catheter and polymicrobial bacteriuria (Enterococcus faecalis and Citrobacter freundii), initiate empiric therapy with vancomycin PLUS a third-generation cephalosporin (such as ceftriaxone) or a fourth-generation cephalosporin (such as cefepime), pending susceptibility results.

Rationale for Dual Coverage

This polymicrobial infection requires coverage of both Gram-positive (Enterococcus) and Gram-negative (Citrobacter) organisms. The 2024 EAU guidelines recommend combination therapy for complicated UTIs, specifically suggesting amoxicillin plus an aminoglycoside, a second-generation cephalosporin plus an aminoglycoside, or an intravenous third-generation cephalosporin 1. However, given the presence of Enterococcus faecalis, which requires specific coverage, and the patient's indwelling catheter status, a modified approach is warranted.

Coverage for Enterococcus faecalis

• Ampicillin is the drug of choice for ampicillin-susceptible enterococci 2
• However, since susceptibilities are not yet available, vancomycin should be used empirically if ampicillin resistance is suspected 2
• The 2015 ESMO guidelines specifically recommend vancomycin for empiric treatment of catheter-related infections when Enterococcus is suspected 3
• For catheter-associated infections, enterococci account for approximately 10% of nosocomial bloodstream infections, with E. faecium showing 60% vancomycin resistance and E. faecalis showing 2% vancomycin resistance 2

Coverage for Citrobacter freundii

• Citrobacter species are Gram-negative rods that commonly cause catheter-associated UTIs 1
• Third- or fourth-generation cephalosporins provide reliable coverage for most Citrobacter species
• The 2024 EAU guidelines support using third-generation cephalosporins for complicated UTIs 1
• Alternative agents include carbapenems or beta-lactam/beta-lactamase combinations if local resistance patterns suggest cephalosporin resistance 3

Critical Management Steps

1. Catheter Management

Remove or replace the indwelling catheter immediately 2. The IDSA guidelines state that removal of infected short-term intravascular catheters is recommended, and for catheter-associated UTIs, catheter removal should be strongly considered 2. The duration of catheterization is the most important risk factor for CA-UTI development 1.

2. Obtain Cultures Before Treatment

• Collect paired blood cultures from a peripheral vein before starting antibiotics 3
• If bacteremia is suspected (fever, rigors, altered mental status), blood cultures are mandatory 1, 4
• Urine culture should ideally be obtained after catheter replacement to avoid contamination 5

3. Tailor Therapy Based on Susceptibilities

Once susceptibility results are available:

For Enterococcus faecalis:

• Switch to ampicillin if susceptible (drug of choice) 2
• Continue vancomycin if ampicillin-resistant 2
• Consider ampicillin plus ceftriaxone as an alternative double beta-lactam regimen if aminoglycosides are contraindicated 6, 2
• The role of combination therapy (cell wall-active antimicrobial plus aminoglycoside) for enterococcal catheter-related infection without endocarditis remains unresolved 2

For Citrobacter freundii:

• Adjust based on susceptibility to cephalosporins
• Consider fluoroquinolones, carbapenems, or piperacillin-tazobactam if cephalosporin-resistant 7

4. Treatment Duration

• 7-14 days is recommended for uncomplicated catheter-associated UTI after catheter removal 2
• 14 days for men when prostatitis cannot be excluded 1
• If the catheter is retained (not recommended), use antibiotic lock therapy in addition to systemic therapy 2, 3

5. Monitor for Complications

Assess for endocarditis risk with Enterococcus faecalis:

• Perform transesophageal echocardiography (TEE) if: new murmur, embolic phenomena, prolonged bacteremia/fever >72 hours despite appropriate therapy, septic pulmonary emboli, or prosthetic valve present 2
• The risk of endocarditis with enterococcal catheter-related infection is relatively low (1.5% in one large study), but persistent bacteremia warrants evaluation 2
• If endocarditis is confirmed, extend treatment to 4-6 weeks 2

Follow-up blood cultures:

• Obtain if fever or bacteremia persists >72 hours after initiating appropriate therapy 2
• Enterococcal bacteremia persisting >4 days is independently associated with mortality 2

Common Pitfalls to Avoid

1. Do not treat asymptomatic bacteriuria in catheterized patients—bacterial colonization occurs in nearly all patients with indwelling catheters and does not require treatment unless symptomatic 1, 5

2. Do not use linezolid empirically—it is not recommended for empirical use in catheter-related infections 3

3. Do not rely on urinalysis alone—in catheterized patients, pyuria and bacteriuria are expected findings and do not confirm infection without clinical symptoms 4, 8

4. Avoid monotherapy for polymicrobial infections—both organisms must be covered empirically until susceptibilities guide de-escalation

5. Do not forget to assess renal function—this 78-year-old patient may require dose adjustments for vancomycin and aminoglycosides (if used) 6

Alternative Regimens

If vancomycin is contraindicated or local resistance patterns suggest high vancomycin MIC (≥2 μg/mL):

• Daptomycin can be used for Enterococcus coverage 3
• Maintain Gram-negative coverage with cephalosporin or carbapenem

If severe sepsis or hemodynamic instability is present:

• Consider adding an aminoglycoside (gentamicin) to the regimen for enhanced Gram-negative coverage 1
• Monitor renal function and aminoglycoside levels closely in this elderly patient